9IQQ

Crystal structure of PKM2 in complex with a natural activator

9IQQ の概要

• エントリーDOI: 10.2210/pdb9iqq/pdb
• 分子名称: Pyruvate kinase PKM, GLUTATHIONE, 1,6-di-O-phosphono-beta-D-fructofuranose, ... (4 entities in total)
• 機能のキーワード: pyruvate kinase, tetramer, activator, transferase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 242080.67

構造登録者

Chen, T.J.,Wang, W.C. (登録日: 2024-07-13, 公開日: 2025-11-19, 最終更新日: 2026-02-11)

主引用文献

Chen, T.J.,Lo, C.J.,Wu, M.J.,Sit, W.Y.,Hsu, H.Y.,Huang, Y.C.,Lu, C.H.,Chen, Y.L.,Fang, W.K.,Yang, S.M.,Chen, P.L.,Haraguchi, T.,Hiraoka, Y.,Lin, C.Y.,Cheng, M.L.,Yang, M.H.,Kung, H.J.,Wang, W.C.
GSH as an A-A Type Allosteric Activator of PKM2: Modulating Cancer Cell Homeostasis and Ferroptosis Susceptibility.
Adv Sci, 13:e19368-e19368, 2026

PubMed Abstract: This study identifies glutathione (GSH) as an endogenous A-A type allosteric activator of pyruvate kinase M2 (PKM2), stabilizing it in its active tetrameric form through binding at the A-A interface. This PKM2-GSH interaction links GSH metabolism to ferroptosis regulation. Transcriptomic analyses across cancers demonstrate strong correlations between GSH, SLC7A11, PKM2, glycolysis, and ferroptosis pathways. By depleting GSH and activating PKM2, ferroptosis is enhanced in PKM2-dependent cancer models. This approach leads to significant changes in central carbon and lipid metabolism, disrupts mitochondrial function, and drives ferroptotic cell death. The combined treatment markedly suppresses tumor growth in a xenograft model. Elevated PKM2 and SLC7A11 expression levels correlate with poorer survival outcomes, indicating their potential as biomarkers for ferroptosis-based therapy. The findings demonstrate a dual role for GSH in cellular homeostasis and identify the PKM2-GSH-SLC7A11 axis as a therapeutic target for aggressive cancers.

PubMed: 41215470
DOI: 10.1002/advs.202519368

実験手法

X-RAY DIFFRACTION (2.7 Å)